Active Pharmaceutical Ingredients (APIs)

Category: *CDMO

Booth No: N/A

Characteristic

We provide the high quality active pharmaceutical ingredients globally. We are one of the leading manufacturers of active pharmaceutical ingredients in the world.
Anticancers
Imatinib Mesylate (TW, US)
Nintedanib Esylate (US, TW, EU)
Pazopanib HCI (TW, US, UA, KR, CN, CA, EU, NZ, SG, ZA, BR ,CH, UK)
Rucaparib Camsylate(US)
Temozolomide (US, RU, TW, KR, SG, CA, AU, CN, JP, BR, CEP, MX, CH, EU)

Anti-inflammatory and
Analgesic Agents
Balsalazide Disodium Dihydrate
(US, TW)
Capsaicin
(US, EU, TW, TR, CA, CN, UK)
Elagolix Sodium(US)
Nonivamide (EU, RU, TW)

MRI Enhancing Agents
Gadoterate Meglumine (US, TR,
CN, EU, TW)

Respiratory Agents
Benzonatate (US, TW, CN, KR)

Cholesterol and Phosphate Binders
Colesevelam HCl(US, TW, IN, TR, CN, EU, CA)
Colestipol HCl USP (US, TW)
Sevelamer HCl (US, TW, CA)
Sevelamer Carbonate (US, EU, TW, CA, IN, TR, AR, AU,CN, MY, KR, SG, SA, IL, TH, ZA, CH, UK)

CNS Agents
Taltirelin Hydrate(JP)
Fludiazepam(TW)

Immunomodulators
Leflunomide (US, CEP, TW, CA, BR, RU, NZ)Mycophenolate Mofetil (US, TW, IN, RU, KR, EU, AU, UK)
Mycophenolate Sodium (US)
Teriflunomide (US, AU, TR, IL, CA, EU, RU, UK, CH)

Steroids
Levonorgestrel (US, TW, ZA, KZ, JP, UA, KR, BR, EU)Mifepristone (US, TW)

Vit. D Derivatives
Alfacalcidol (EU, TW, CN, SA, IN, RU, JP)
Calcifediol (CEP, US)
Calcipotriol Anhydrous (TW, US, CN, CEP, IN, CA, BY, EU)
Calcipotriol Monohydrate (US, CEP, IN, TW, TR, BY, DZ, MY, CN, CA, PH, AU)Calcitriol (US, CEP, TW, CA, KR, IN, PK, BR, MX, JP, CN, EU)Doxercalciferol (US, TW)
Maxacalcitol (JP, TW)Paricalcitol (US, EU, TW, CN, KR, IN, IL, TR, MY, MK, NZ, BR)

Antibiotics
Linezolid (US, EU, JP, CA, AU, TW, BR, KR, MY, ZA, CN, UK)

Potassium Binders
Patiromer Sorbitex Calcium (US)

Others
Ecamsule

Please be reminded that some products listed above are still patented and can only be made available for R & D use as permitted under 35 USC ¶ 271 (e) (1); Article 69, Paragraph 1 of the Patent Act of Japan; Directive 2004/27/EC of the European Parliament and of the Council of 31 March 2004; or Article 69 (5) of the Patent Law of People’s Republic of China; or Article 60 of the Patent Act of Republic of China. We will not make, sell, offer for commercial sale or export the products listed above in/into regions or countries in which substance patents are still existing and we will not be responsible if the use of any of the above products infringes on any patent in your country.